0001348362-24-000002.txt : 20240730
0001348362-24-000002.hdr.sgml : 20240730
20240730112541
ACCESSION NUMBER: 0001348362-24-000002
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240726
FILED AS OF DATE: 20240730
DATE AS OF CHANGE: 20240730
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Baxter Nicholas W
CENTRAL INDEX KEY: 0001312326
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39874
FILM NUMBER: 241155550
MAIL ADDRESS:
STREET 1: 37H KING'S GATE
STREET 2: ABERDEEN
CITY: ABERDEENSHIRE, SCOTLAND
STATE: X0
ZIP: AB15 4EL
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lexaria Bioscience Corp.
CENTRAL INDEX KEY: 0001348362
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 202000871
STATE OF INCORPORATION: NV
FISCAL YEAR END: 0831
BUSINESS ADDRESS:
STREET 1: 100 - 740 MCCURDY ROAD
CITY: KELOWNA
STATE: A1
ZIP: V1X 2P7
BUSINESS PHONE: 250-765-6424
MAIL ADDRESS:
STREET 1: 100 - 740 MCCURDY ROAD
CITY: KELOWNA
STATE: A1
ZIP: V1X 2P7
FORMER COMPANY:
FORMER CONFORMED NAME: LEXARIA CORP.
DATE OF NAME CHANGE: 20080229
FORMER COMPANY:
FORMER CONFORMED NAME: Lexaria Corp.
DATE OF NAME CHANGE: 20051229
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0508
4
2024-07-26
0
0001348362
Lexaria Bioscience Corp.
LEXX
0001312326
Baxter Nicholas W
37H KING'S GATE
ABERDEEN
ABERDEENSHIRE, SCOTLAND
X0
AB15 4EL
UNITED KINGDOM
1
0
0
0
0
common shares
11000
D
Stock Options
3
2021-04-26
2026-04-26
Common Shares
1500
1500
D
Stock Options
3
2021-06-08
2026-06-08
Common Shares
5000
6500
D
Stock Options
3
2021-09-01
2026-09-01
Common Shares
1900
8400
D
Stock Options
3.39
2022-03-08
2027-03-08
Common Shares
3400
11800
D
Stock Options
1.96
2022-10-12
2027-10-12
Common Shares
18200
30000
D
Stock Options
0.87
2023-07-25
2028-07-25
Common Shares
5000
35000
D
Stock Options
2.36
2024-04-26
2029-04-26
Common Shares
5000
40000
D
Stock Options
3.39
2024-07-26
4
A
0
12000
0
A
2024-07-26
2029-07-26
Common Shares
12000
52000
D
Repriced from $5.31 pursuant to shareholder approval received May 9, 2023
Repriced from $7.08 pursuant to shareholder approval received May 9, 2023
Repriced from $6.23 pursuant to shareholder approval received May 9, 2023
/Nicholas Baxter/
2024-07-30